Results for: Breast

35 Trials Avaliable

  • BRE 225

    A phase 1, open-label, dose escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

  • BRE 237

    A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locallky Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regiments for Metastatic Disease

  • BRE 253

    A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR)

  • BRE 285

    A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER

  • BRE 300

    A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH HORMONE RECEPTOR'{POSITIVE HER2-NEGATIVE BREAST CANCER (MORPHEUS-HR+ BREAST CANCER)

  • BRE 310

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) INCOMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

  • BRE 321

    A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer

  • BRE 323

    Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer

  • BRE 324

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human EpidermalnGrowth Factor Receptor 2-Negative (ER+/HER2') Breast Cancer (KEYNOTE-756)n

  • BRE 326

    A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer

  • BRE 330

    A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer

  • BRE 335

    A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting

  • BRE 336

    A Phase 2 Study of TAS-120 in Metastatic Breast Cancers HarboringnFibroblast Growth Factor Receptor (FGFR) Amplifications

  • BRE 342

    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR?POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • BRE 344

    A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer

  • BRE 349

    An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor'Positive HER2-Negative Breast Cancer

  • BRE 352

    A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer

  • BRE 353

    Protocol Title: A Phase III, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation

  • BRE 354

    A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer

  • BRE 355

    A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic Hormone Receptor (HR)-positive, HER2-negative breast cancer

  • BRE 358

    A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

  • BRE 360

    Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)

  • BRE 363

    A Phase 1b/2 Multicenter, Open-label, Dose Expansion Study to Explore the Safety, Tolerability, and Anti-tumor Activity of Trastuzumab Deruxtecan (DS 8201a, T-DXd) Monotherapy and Combinations in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)

  • BRE 364

    A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

  • BRE 365

    A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer

  • BRE 375

    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

  • BRE 383

    A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

  • BRE 388

    Phase 3, Open Label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) versus Investigator's Choice Chemotherapy in inoperable or Metastatic Hormone Receptor-positive, HER2-negative, Breast Cancer patients who have been treated with one or two lines of systemic chemotherapy in the metastatic setting

  • BRE 389

    postM0NARCH: A Randomized, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant or Abemaciclib plus LY3484356 to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor and Endocrine Therapy

  • BRE 390

    A phase III trial of neoadjuvant Trastuzumab Deruxtecan monotherapy or Trastuzumab Deruxtecan in sequence with paclitaxel + trastuzumab + pertuzumab vs doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab in HER2-positive early breast cancer (Destiny-Breast11)

  • BRE 391

    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer

  • MULTI 48

    A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

  • OUTCOMES 02

    Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane use in Metastatic Breast Cancer

  • RM 842

    A First-in-Human Study of Mutant-Selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

  • RM 887

    A Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation